Microbial Physiology
Short Communication
Involvement of Heat Shock Proteins in Candida albicans Biofilm FormationBecherelli M. · Tao J. · Ryder N.S.Infectious Diseases, Novartis Institutes for Biomedical Research Inc., Cambridge, Mass., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: August 07, 2013
Issue release date: October 2013
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1
ISSN: 2673-1665 (Print)
eISSN: 2673-1673 (Online)
For additional information: https://www.karger.com/MIP
Abstract
Biofilm growth represents one of the most challenging problems associated with Candida infections, largely due to the natural resistance of biofilm to the common antifungal drugs. As elevated expression of heat shock proteins (HSP) promotes Candida yeast-hyphae switch, which is an essential step in biofilm formation, we investigated the expression of hsp genes during Candida albicans biofilm development. By measuring mRNA levels using qRT-PCR, we found that all three hsp genes that we monitored are overexpressed in the initial stage of C. albicans biofilm formation. To corroborate this finding, we examined the effect of 17-DMAG, a specific Hsp90 inhibitor, on the formation of C. albicans biofilm. Our results indicate the requirement of HSP during the early phase of Candida biofilm development.
© 2013 S. Karger AG, Basel
Related Articles:
References
- Baillie GS, Douglas LJ: Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 1998;42:1900-1905.
- Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA: Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001;183:5385-5394.
-
Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard - third edition. CLSI document M27-A3. Wayne, CLSI, 2008.
- Cowen LE, Lindquist S: Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005;309:2185-2189.
- Dabrowa N, Howard DH: Heat shock and heat stroke proteins observed during germination of the blastoconidia of Candida albicans. Infect Immun 1984;44:537-539.
- Finkel JS, Mitchell AP: Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 2011;9:109-118.
- Finkel JS, Xu W, Huang D, Hill EM, Desai JV, Woolford CA, Nett JE, Taff H, Norice CT, Andes DR, Lanni F, Mitchell AP: Portrait of Candida albicans adherence regulators. PLoS Pathog 2012;8:e1002525.
-
Hawser SP, Norris H, Jessup CJ, Ghannoum MA: Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2h-tetrazolium hydroxide (XTT) colorimetric method with the Standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol 1998;36:1450-1452.
- Kuhn DM, Ghannoum MA: Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Invest Drugs 2004;5:186-197.
- Murillo LA, Newport G, Lan CY, Habelitz S, Dungan J, Agabian NM: Genome-wide transcription profiling of the early phase of biofilm formation by Candida albicans. Eukaryot Cell 2005;4:1562-1573.
- Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr, Mowat E, Ramage G, Lopez-Ribot JL: A simple and reproducible 96-well-plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 2008;9:1494-1500.
- Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL: Candida biofilms: an update. Eukaryot Cell 2005;4:633-638.
- Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE: Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 2011;7:e1002257.
- Seneviratne CJ, Wang Y, Jin L, Abiko Y, Samaranayake LP: Candida albicans biofilm formation is associated with increased anti-oxidative capacities. Proteomics 2008;8:2936-2947.
- Shapiro R, Uppuluri P, Zaas AK, Collins C, Senn H, Perfect JR, Heitman J, Cowen LE: Hsp90 orchestrates temperature dependent Candida albicans morphogenesis via Ras1-PKA signalling. Current Biol 2009;19:1-9.
- Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM: Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005;56:126-137.
- Swoboda RK, Bertram G, Budge S, Gooday GW, Gow NA, Brown AJ: Structure and regulation of the Hsp90 gene from the pathogenic fungus Candida albicans. Infect Immun 1995;63:4506-4514.
Article / Publication Details
Published online: August 07, 2013
Issue release date: October 2013
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1
ISSN: 2673-1665 (Print)
eISSN: 2673-1673 (Online)
For additional information: https://www.karger.com/MIP
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
